Cambridge, UK, 05 October 2021: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the commercial launch of its Oncology Service in response to the global need to improve cancer drug discovery approval rates.
News
Cambridge, UK, 05 October 2021: Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Dr. Louise Modis as Chief Scientific Officer, following the recent completion of a $33 million USD Series A funding.
Today marks the launch of Patent Enforcement in the UK and Trans-Pacific Countries, an essential guide for private practitioners, in-house lawyers and other professionals with responsibility for intellectual property who are interested in the Trans-Pacific region.
Published by Globe Law and Business, the guide features contributions by Taylor Wessing experts Paul England, Amanda Ebbutt and Tom Foster, as well as a number of leading patent lawyers from Australia, Canada, US, Japan, South Korea, Singapore and New Zealand.
We have helped secure the sale of the private healthcare company behind London's Parkside and Highgate hospitals.
The deal saw Aspen Healthcare, which runs eight hospitals and clinics around the UK, sold to NorthWest Healthcare Properties Real Estate Investment Trust.
The Canadian-based healthcare property trust took over in August this year, but it already owned some of the sites leased by Aspen Healthcare.
New research reveals the confidence and capability of business in addressing international trade concerns.
In-Brief:
What are trade teams being asked to support and how confident do they feel in meeting business needs?
To deliver long-term value, what practical steps are needed to move from just the ‘basics’ to best in class?
How do UK companies differ from their global peers and how do they define their trade strategy?
Edinburgh and Cambridge, UK, 1 October 2021 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made five new appointments to its scientific team, to support and accelerate its R&D.
Click here to view the September edition of Dates for Your Diary
Click here to read the full edition of the September 2021 People Pathways newsletter.
A Newcastle biotech, specialising in nanorobotic technology to improve the diagnosis of some of the world’s most serious diseases, has joined Newcastle Helix.
Nanovery, a biotechnology company formed in 2018, are developing nanorobots for a quick and easy test to help in the diagnosis of cancer and other diseases. The test is based on DNA nanotechnology and costs less than tissue biopsy, whilst reducing risk to patients.
CAMBRIDGE, UK and NEW YORK, USA, 28 September 2021: Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA Damage Response process in order to treat patients suffering from a broad range of cancers, announces it has dosed the first patient in its Phase 1/2a study with its polymerase theta (Polθ) inhibitor, ART4215. The Polθ project was originally in-licensed from Cancer Research UK in 2016 as part of the initial formation of Artios.